{"id":"W3214080616","doi":"10.1016/s2152-2650(21)01925-x","title":"TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Prednisone; Vincristine; CHOP; Clinical endpoint; Progression-free survival; Anaplastic large-cell lymphoma; Cyclophosphamide; Phases of clinical research; Gastroenterology; Oncology; Surgery; Lymphoma; Randomized controlled trial; Chemotherapy; CD30","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00212911,0.002044856,0.003090545,0.0004262983,0.0004466595,0.001483459,0.00137248,0.001970447,0.00499791],"category_scores_gemma":[0.00161693,0.0006522102,0.002047365,0.0003831663,0.001383446,0.001646563,0.0004560609,0.003899928,0.001116212],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009911588,"about_ca_system_score_gemma":0.0009621846,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001301779,"about_ca_topic_score_gemma":0.002778246,"domain_scores_codex":[0.9993103,0.0003685603,0.00002991111,0.0001168071,0.00004275225,0.0001316689],"domain_scores_gemma":[0.9989247,0.0002848397,0.0002001166,0.0001013684,0.0000506014,0.0004383515],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9839622,0.003488352,0.0004757229,0.0002094977,0.0007084965,0.00003030904,0.00002867674,0.0003761683,0.001734983,0.00007995504,0.0007041924,0.008201479],"study_design_scores_gemma":[0.9634809,0.0332046,0.001697956,0.00001414105,0.0004190843,0.00003494971,0.00001723197,0.0004321626,0.0002671495,0.0001104529,0.0003056823,0.00001569366],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902581,0.003109417,0.0005560151,0.0006938977,0.0003876641,0.001272063,0.001411901,0.000169274,0.002141733],"genre_scores_gemma":[0.9881672,0.001568323,0.001136316,0.001456645,0.0004620586,0.001538674,0.00250303,0.00005380652,0.003113863],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00499791,"threshold_uncertainty_score":0.0167197,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04101108403857088,"score_gpt":0.3430992426875918,"score_spread":0.3020881586490209,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}